Roxanne Penghlis

Background:

Geneva, 20 April 2022 -- Médecins Sans Frontières/Doctors Without Borders (MSF) welcomes the updated World Health Organization (WHO) guidelines for the management of cryptococcal meningitis, an opportunistic fungal infection, which is the number two killer of people living with HIV/AIDS after tuberculosis. The guidelines endorse a simplified regimen, following the important results of the AMBITION trial, consisting of a single high dose of liposomal amphotericin B (L-AmB), combined with two weeks of flucytosine and fluconazole, as the preferred treatment option. With new WHO global targets set to reduce deaths from cryptococcal meningitis by 50% in 2025 and 90% by 2030, MSF urges all countries to urgently adopt these guidelines to save lives of people living with HIV/AIDS.

However, access to L-AmB and flucytosine remains a significant challenge in low- and middle-income countries due to a combination of factors including the drugs not being included in national guidelines and countries not submitting requests to donors such as the Global Fund and PEPFAR to fund the procurement of these lifesaving medicines.

To begin addressing the challenges of accessing L-AmB and flucytosine, governments need to update national cryptococcal meningitis clinical guidance urgently, include these medicines in funding requests from major donors, and increase screening for cryptococcal meningitis among people living with HIV. Governments need to work with pharmaceutical companies and urge them to increase production and expand registration of these medicines to meet the expected increase in demand as countries start to adapt and implement the new guidelines.

Additionally, US corporation Gilead, the main supplier of quality-assured L-AmB, has failed to deliver on its promise of providing this lifesaving medicine at the access price of $16.25 per vial to treat cryptococcal meningitis (which would allow for the inclusion of L-AmB at approximately $195 per person under the new recommended treatment protocol) as promised to 116 countries in 2018. More than three years later, Gilead has still only provided L-AmB to less than half of the eligible countries at the access price. Furthermore, Gilead has done little to expand access in terms of registration of L-AmB where it is needed most -- with registrations in only two countries in all of sub-Saharan Africa. In addition, despite multiple quality-assured generic manufacturers of flucytosine in the market, few have been registered and made available in low- and middle-income countries.

Dr Freddy Mangana, HIV-TB Medical Supervisor for MSF in the Democratic Republic of Congo:

"With timely and effective diagnosis and treatment, people living with HIV/AIDS can survive opportunistic infections like cryptococcal meningitis. We are optimistic that the new treatment regimen recommended in the WHO guidelines will be adopted quickly by countries, as it is much simpler to give, can be started immediately in some settings, is better tolerated and will hopefully lead to shorter hospital stays for many patients. However, the limited availability of quality-assured L-AmB and flucytosine means that treatment providers working in sub-Saharan Africa struggle to treat people with cryptococcal meningitis or risk treating them with suboptimal treatments when these medicines are not available. The good news is that this new regimen also uses less L-AmB and requires less monitoring, which could reduce the overall price for countries to implement as compared to the previous L-AmB regimen, if urgently adopted into national guidelines."

Jessica Burry, HIV pharmacist for MSF's Access Campaign:

"We are encouraged that the WHO guidelines now include a simplified treatment regimen for people with cryptococcal meningitis, but it's disheartening to see the persistent challenges to accessing the required medicines. This lifesaving treatment remains out of reach and unaffordable for far too many people who need it. To ensure we meet the new WHO targets for decreasing deaths from cryptococcal meningitis, Gilead needs to do everything it can to make good on its promise to provide L-AmB at their access price. In addition, there needs to be a significant effort from countries to prioritise the use of L-AmB and flucytosine, and from manufacturers to start registering and supplying these medicines."

Editor's Note

*Liposomal amphotericin B (L-AMB) *

In September 2018, Gilead announced an "access" price for 116 low- and middle-income countries of US$16.25 per vial of L-AmB, an essential medicine for treatment of fungal infections including first line treatment per WHO guidelines for management of cryptococcal meningitis in people living with HIV. However, Gilead has exclusive agreements with distributors in many countries, allowing L-AmB to be sold for prices as high as $200 per vial in South Africa and $70 per vial in India, and limiting where this access price is available. In countries outside of the territory of the access pricing, such as Brazil, L-AmB costs $373 per vial for cryptococcal meningitis in the public health system, bringing total treatment cost with L-AmB alone to approximately $5000. More than three years later, Gilead has still only provided L-AmB to less than half of the eligible countries at the access price.

While L-AmB has been off patent since 2016, generic manufacturers have been working for years to develop this product, hindered by the fact that Gilead maintains trade secrets and has not been willing to facilitate technology transfer. This allows Gilead to maintain its monopoly and high price on this drug. At the end of 2019, Gilead finally got USFDA approval for a new manufacturing site in California, US, so an end to the usual 4-6 months lead time for orders was anticipated in June 2020. However, this was further delayed until the end of the 2021 as this new facility is also used to produce remdesivir, a treatment for COVID-19, effectively displacing production of L-AmB and causing continued delays. The first generic formulation of L-AmB was approved by the USFDA in December 2021, which could potentially alleviate supply constraints if they register and supply in high-burden countries.

Lynsey Morrow, Sales & Marketing Manager

This is one of the best and worst comments I often hear about Campus North. It’s true, Campus North, in my humble opinion, has an incredible atmosphere. You can feel it as soon as you walk through the door.

I've been one of the Campus North team for just over a year now. I’d heard about the place many times before I joined them, but I never really got it. Surely it was just a building full of lots of companies? Big whoop. I didn't understand what made it so special. A considerable amount of time passed before I crossed their threshold. Then it hit me. I get it.

It’s largely (if not entirely) due to the community. There’s an incredible support network of like-minded, innovative, creative people. It’s hard not to feel inspired by them. You overhear many conversations by the kettle, or at Friday beers, of people sharing their problems, their latest successes, asking for help or talking complete nonsense. It’s organic, and it’s priceless.

I came across an article by Entrepreneur that summed it up perfectly. (Have a read of it here.)

If you've read any of our Quick Fire blog posts you’ll have realised that I'm not the only one who thinks this. Here’s a quick recap of some of the responses we received when we asked:

There’s something for everyone. Sometimes you don’t want to be confined to your desk. Maybe you want to lie on the sofa with a big mug of tea and your laptop rested on a cushion. Or maybe you need to take a private call, a communal space won’t cut it. Easy — Nip into one of the telephone booths. There’s quiet areas, those with background noise, cosy areas with sofas or beanbags and meeting rooms for important clients.

There’s colourful murals on the wall, an old school blackboard with a host of events, comic book wallpaper and coworkers who have windmills and confetti attached to their monitors. It’s not your typical office building full of lots of companies.

There’s no doubt that the flexibility and look of the space contributes to that “vibe”.

I love when people comment on the “vibe” of Campus North because I now know exactly what they mean. I know that feeling.

You can’t bottle a “vibe”.

My role in the Campus team is Sales and Marketing Manager. If I could bottle that feeling, that vibe, that buzz, people get when they first walk in, I’d be a very happy girl! (Then again, the might not need me if that was the case!)

Holiday Inn Express Melbourne Southbank, an IHG Hotel

Address: 35/47 City Rd, Southbank VIC 3006, Australia

Cairns Car & 4WD Centre

Address: 28 Hannam St, Bungalow QLD 4870, Australia

We explore one of the bloodiest chapters in New Orleans historyMERCH: We've got it! SHOP NOW: https://bzfdit/2MDBk2dMUSICLicensed via

Philippines Drama with English Subtitle, Philippines Drama with English Subtitle is the best drama app Philippines Drama with English Subtitle download apk

I have resided in New York for 36 years and Cali for 2.I wouldn't live in Cali because it's nice to visit.Finger lakes and Ithaca New York has so many things to offer.When people think of New York, they think of it, but there is more to the city.I moved to Albany from Long Island and I love it!

No one would win Both sides would end up launching nuclear missiles at each other and that would be a one way ticket to hell The survivors would envy the dead

• Car Insurance.
• Comprehensive Car Insurance.
• Own Damage Car Insurance.
• Third Party Car Insurance.
• Two Wheeler Insurance.
• Comprehensive Two Wheeler Insurance.
• Own Damage Two Wheeler Insurance.
• Commercial Vehicle Insurance.

• Start Simple & Learn As You Go.
• Purchase Your Plants From a Local Garden Center.
• Match Your Plants to Your Design Style for a Cohesive Look.
• Liven Up Your Bathroom With High-Humidity Plants.
• Brighten Up Dark Corners With Low-Light Plants.
• Create Contrast With Plants of All Sizes.

• ASOS Marketplace.
• Etsy.
• eBay.
• Poshmark.
• The RealReal.
• Refashioner.
• ThredUP.
• LePrix.